Watch XFOR. Know when insiders buy.
One email the day a filing lands. Free.
XFOR
X4 Pharmaceuticals, Inc
2.83
+0.00 +0.00%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $280.6MP/E 141.5DIV YIELD —FCF YIELD —REV TTM $8.7M +86.0%NET INCOME −$90.1MNET CASH $120.1M52W 2.83 – 4.67SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.4M | +41.2% | 32.6% | −$16.4M | −$16.2M | — | -0.13 | −$20.8M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $2.5M | +177.8% | 76.1% | −$20.3M | −$20.2M | −7277.7% | -0.16 | −$19.6M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $2.2M | +46.7% | 83.5% | −$23.7M | −$23.9M | — | 1.00 | −$15.5M | $0 | −$15.5M | Mar 17 |
| Q3 2025 · Sep 30 | $1.6M | +179.6% | 77.6% | −$27.5M | −$29.8M | — | -0.69 | −$27.8M | $0 | −$27.8M | Nov 5 |
| Q2 2025 · Jun 30 | $1.7M | +202.0% | 80.8% | −$26.2M | −$25.7M | −128.3% | -3.47 | −$29.9M | $0 | −$29.9M | Aug 6 |
| Q1 2025 · Mar 31 | $900K | — | -424.0% | −$9.4M | $282K | — | 0.04 | −$12.4M | $0 | −$12.4M | Aug 6 |
| Q4 2024 · Dec 31derived | $1.5M | — | 79.9% | −$35.7M | −$39.8M | — | -5.94 | −$33M | $41K | −$33M | Mar 17 |
| Q3 2024 · Sep 30 | $560K | — | 59.5% | −$34.5M | −$36.7M | — | -5.48 | −$34M | $92K | −$34.1M | Nov 5 |
| Q2 2024 · Jun 30 | $563K | — | 52.4% | $71.1M | $90.8M | — | 13.57 | −$63.9M | $134K | −$64M | Nov 5 |
| Q1 2024 · Mar 31 | $0 | — | — | −$37.3M | −$51.8M | — | -7.77 | −$33.6M | $59K | −$33.7M | Nov 5 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$25.2M | −$19.1M | — | -16.59 | −$27.7M | $35K | −$27.8M | Mar 17 |
| Q3 2023 · Sep 30 | $0 | — | — | −$27.2M | −$2.3M | — | -0.01 | −$68.8M | $8K | −$68.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6.5M | 11.4% | −$86.9M | −$79.2M | -1218.4% | -1.87 | −$85.6M | $0 | −$85.6M | — | — |
| FY2024 · to Dec 31 | $2.6M | 69.3% | −$36.4M | −$37.5M | -1440.4% | -5.59 | −$130.9M | $326K | −$131.2M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$107.5M | −$101.2M | — | -17.07 | −$96.5M | $60K | −$96.6M | $0 | — |
| FY2022 · to Dec 31 | $0 | — | −$87.6M | −$93.9M | — | -1.52 | −$77.1M | $103K | −$77.2M | $0 | — |
| FY2021 · to Dec 31 | $0 | — | −$85.1M | −$88.7M | — | -3.99 | −$70.9M | $615K | −$71.5M | $2M | — |
| FY2020 · to Dec 31 | $3M | — | −$59.9M | −$62.1M | -2071.0% | -3.09 | −$58.8M | $1.4M | −$60.2M | $0 | — |
Every number comes from X4 Pharmaceuticals, Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.